or
Remember me
Back
BNHLF has a niche drug in their hands with lots of potential.
The shortcomings of the Phase 3 study are not insurmountable.
This stock is significantly undervalued, especially after the ADCOM announcement.
A daily snapshot of everything from market open to close.